EUCTR2009-018148-45-IT进行中（未招募）1 期
An exploratory Phase 2 study of Pemetrexed and Cisplatin as Preoperative chemotherapy in the treatment of Stage IIIAN2 nonsquamous non-Small cell lung cancer - ND
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Histologic diagnosis of NSCLC defined as other than predominantly squamous cell histology (squamous cell and/or mixed small cell, non-small cell histology is not permitted). [2] Stage IIIAN2 disease (T1aN2, T1bN2, T2aN2, T2bN2, and T3N2) (except pancoast tumors and bronchoalveolar carcinoma) as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer. [3] Tumor considered potentially resectable with no evidence of extrathoracic metastatic disease. [4] ECOG PS of 0 or 1. [5] No prior surgery, radiotherapy, systemic chemotherapy, immunotherapy, targeted, or biological therapy for NSCLC. [6] At least 1 unidimensionally measurable lesion meeting RECIST criteria version 1.1 (at least 10 mm in longest diameter [LD] by CT scan [slice thickness 5mm], or at least 20 mm LD by chest X-ray). For malignant lymph nodes, at least 15 mm in short axis when assessed by CT scan (slice thickness 5 mm). PET scans and ultrasounds may not be used for tumor measurements. [7] Estimated life expectancy of at least 6 months [8] Patient compliance and geographic proximity that allow adequate follow-up. [9] Adequate organ function including the following: Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) > or =1.5 x 109/L, platelets > or =100 x 109/L, and hemoglobin > or = 9 g/dL. Hepatic: bilirubin < or = 1.5 times the upper limit of normal (x ULN), alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) < or = 3.0 x ULN. Renal: calculated creatinine clearance (CrCl) > or = 45 mL/min based on the original weight-based Cockroft and Gault formula and serum creatinine < or = 1.5 x ULN. [10] Patients must sign an informed consent document (ICD). [11] Patients must be at least 18 years of age. [12] For women: Must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen (for example, intrauterine device, birth control pills, or barrier device) during and for 6 months after last dose of study drug; must have a negative serum or urine pregnancy test within 7 days before study enrollment; and must not be breast-feeding. For men: Must be surgically sterile, or compliant with a contraceptive regimen during and for 6 months after last dose of study drug. [13] Patients must have an adequate tumor tissue sample available for detection of biomarkers expression. [14] Predicted postresection forced expiratory volume in 1 second (FEV1) > or =1.2 L. [15] Patients must be fit for surgery at time on enrollment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[16] Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. [17] Have previously completed or withdrawn from this study or any other study investigating pemetrexed. [18] Have a serious concomitant systemic disorder (for example, active infection including human immunodeficiency virus) that, in the opinion of the investigator, would compromise the patient’s ability to adhere to the protocol. [19] Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV. [20] Have had a prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. Patients with a history of low grade (Gleason score < or =6) localized prostate cancer will be eligible even if diagnosed less than 5 years previously. [21] Are receiving concurrent administration of any other antitumor therapy. [22] Have received a recent (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination. [23] Are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose < or = 1.3 grams per day. [24] Are unable or unwilling to take folic acid, vitamin B12 supplementation, or corticosteroids. [25] Have had significant (>5%) weight loss within 6 months of enrollment.
研究者
相似试验
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEstudio en fase II de pemetrexed en combinación con cisplatino y cetuximab en el carcinoma de células escamosas de cabeza y cuello recurrente o metastásicoRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCarcinoma de células escamosas de cabeza y cuello recurrente o metastásicoMedDRA version: 12.0Level: LLTClassification code 10063569Term: Metastatic squamous cell carcinomaEUCTR2009-011611-21-ESEli Lilly and Company Ltd.65
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEUCTR2009-011611-21-DEEli Lilly and Company Ltd.65
进行中（未招募）
1 期
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEUCTR2009-011611-21-GBEli Lilly and Company Ltd.65
进行中（未招募）
1 期
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckMedDRA version: 13.1Level: PTClassification code 10063569Term: Metastatic squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011611-21-BEEli Lilly and Company Ltd.65
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck - NDRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckMedDRA version: 9.1Level: LLTClassification code 10063569EUCTR2009-011611-21-ITEli Lilly and Company Ltd.